EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification

Hironao Okubo iD, Hitoshi Ando, Shunsuke Nakamura, Yusuke Takasaki, Koichi Ito, Yuka Fukuo, Kenichi Ikejima, Hiroyuki Isayama

Cancer Medicine · 2024

DOI: 10.1002/cam4.70222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hironao Okubo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Anilides, Pyridines, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the outcomes of cabozantinib in patients with unresectable hepatocellular carcinoma (uHCC), focusing on dose setting and modification.

Methods

We retrospectively analyzed 34 Japanese patients who received cabozantinib for uHCC. Trough concentrations (C trough ) of cabozantinib were also measured weekly for 6 weeks in the 18 patients.

Results

Sixteen patients received ≥40 mg (high‐dose group), and 18 patients received 20 mg (low‐dose group). Dose escalations were performed in 27.8% of the patients in the low‐dose group. Although median duration of the first dose reduction or interruption in the low‐dose group was twice that in the high‐dose group (28 vs. 14 days, p < 0.001), there were no significant differences in the relative dose intensity (RDI) during 6 weeks, progression free survival (PFS), and overall survival ( p = 0.162, p = 0.950, p = 0.817, respectively) between the two groups. Patients who received RDI during 6 weeks ≥33.4% showed a trend toward longer median PFS ( p = 0.054). Each serum aldolase value during the 6 weeks was significantly correlated with the C trough at any point ( r = 0.500, p < 0.001). In multivariate analyses, aldolase ≥8.7 U/L within 2 weeks was significantly associated with the very early dose reduction or interruption (odds ratio 20.0, p = 0.002).

Conclusions

An initial dose of 20 mg cabozantinib could be a safe option in Japanese patients. The serum aldolase value could be useful for making appropriate dose modifications of cabozantinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAnilidesPyridinesLiver NeoplasmsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAntineoplastic AgentsDose-Response Relationship, DrugProtein Kinase InhibitorsTreatment OutcomeProgression-Free SurvivalAdult

Stichwörter der Autor:innen

aldolasecabozantinibdose modificationhepatocellular carcinomamuscle injuryrelative dose intensity

Substanzen

cabozantinibAnilidesPyridinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Cellular and Molecular Function Analysis, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan.

ORCID-Profile: Hironao Okubo

Zitieren

APA

Okubo, H., Ando, H., Nakamura, S., Takasaki, Y., Ito, K., Fukuo, Y., Ikejima, K., & Isayama, H. (2024). Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification. Cancer Medicine. https://doi.org/10.1002/cam4.70222

Vancouver

Okubo H, Ando H, Nakamura S, Takasaki Y, Ito K, Fukuo Y, et al. Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification. Cancer Medicine. 2024. doi:10.1002/cam4.70222

BibTeX
@article{Okubo2024,
  author = {Okubo, Hironao and Ando, Hitoshi and Nakamura, Shunsuke and Takasaki, Yusuke and Ito, Koichi and Fukuo, Yuka and Ikejima, Kenichi and Isayama, Hiroyuki},
  title = {Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70222}
}
Kostenlos starten →